reports
Bread Financial to Participate in the UBS Financial Services Conferenc...
Bread Financial to Participate in the UBS Financial Services Conference COLUMBUS, Ohio, Feb. 04, 2026 (GLOBE NEWSWIRE) -- (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions, today announced the company’s participation in the UBS Financial Services Conference on Wednesday, February 11. Bread Financial EVP and Chief Financial Officer Perry Beberman will participate in a fireside chat. The fireside chat will take place at 12:10 p.m. ET and will be broadcast live . The fireside chat can also be accessed through B...
Bread Financial to Participate in the Bank of America 2026 Financial S...
Bread Financial to Participate in the Bank of America 2026 Financial Services Conference COLUMBUS, Ohio, Feb. 03, 2026 (GLOBE NEWSWIRE) -- (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions, today announced the company’s participation in the Bank of America 2026 Financial Services Conference on Tuesday, February 10. Bread Financial President and Chief Executive Officer Ralph Andretta, along with EVP and Chief Financial Officer Perry Beberman will participate in a fireside chat. The fireside chat will take plac...
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
NFLX NETFLIX INC.
FRX_CN FENNEC PHARMACEUTICALS
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
GOSS GOSSAMER BIO
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ZNTL KEROS THERAPEUTICS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
PRAX LARIMAR THERAPEUTICS INC
U PRAXIS PRECISION MEDICINES
TVTX UNITY SOFTWARE
DASH TRAVERE THERAPEUTICS INC
VRDN DOORDASH
PLTK VIRIDIAN THERAPEUTICS INC
RBLX PLAYTIKA HOLDING
DAWN ROBLOX
STX DAY ONE BIOPHARMACEUTICALS INC
APP SEAGATE TECHNOLOGY HLDGS PLC
GFS APPLOVIN CORP
GMTX GLOBALFOUNDRIES INC
TYRA GEMINI THERAPEUTICS INC
EWTX TYRA BIOSCIENCES INC
SLDB EDGEWISE THERAPEUTICS INC
APGE SOLID BIOSCIENCES INC
DNTH APOGEE THERAPEUTICS INC
CGON DIANTHUS THERAPEUTICS INC
ORKA CG ONCOLOGY INC
BCAX ORUKA THERAPEUTICS INC
ZBIO BICARA THERAPEUTICS INC.
TLX ZENAS BIOPHARMA INC.
MAZE TELIX PHARMACEUTICALS LIMITED
JBIO MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Robert Driscoll
- Thomas Yip
- Yun Zhong
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
SLDB SOLID BIOSCIENCES INC
APGE APOGEE THERAPEUTICS INC
DNTH DIANTHUS THERAPEUTICS INC
ORKA ORUKA THERAPEUTICS INC
BCAX BICARA THERAPEUTICS INC.
ZBIO ZENAS BIOPHARMA INC.
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
JBIO JADE BIOSCIENCES INC
Bread Financial Provides Performance Update for December 2025
Bread Financial Provides Performance Update for December 2025 COLUMBUS, Ohio, Jan. 29, 2026 (GLOBE NEWSWIRE) -- (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company’s net loss rate and delinquency rate for the periods indicated: For themonth endedDecember 31, 2025 For thethree months endedDecember 31, 2025 (dollars in millions)End-of-period credit card and other loans$18,805 $18,805 Average credit card and ot...
Bread Financial Reports Fourth Quarter and Full Year 2025 Results
Bread Financial Reports Fourth Quarter and Full Year 2025 Results COLUMBUS, Ohio, Jan. 29, 2026 (GLOBE NEWSWIRE) -- (NYSE: BFH), a tech-forward financial services company that provides simple, flexible payment, lending and saving solutions, today announced its fourth quarter and full year 2025 financial results. All earnings-related materials are now available at the company’s investor relations website, . Bread Financial President and Chief Executive Officer Ralph Andretta and Chief Financial Officer Perry Beberman will host a conference call at 8:30 a.m. ET today to discuss results. A...
Bread Financial Declares Dividends on Preferred and Common Stock
Bread Financial Declares Dividends on Preferred and Common Stock COLUMBUS, Ohio, Jan. 29, 2026 (GLOBE NEWSWIRE) -- . (NYSE: BFH), a tech-forward financial services company that provides simple, flexible payment, lending and saving solutions, today announced that its Board of Directors declared quarterly dividends on its preferred and common stock for the first quarter of 2026. On the Company’s 8.625% Non-Cumulative Perpetual Preferred Stock, Series A (NYSE: BFH-PrA), the Board of Directors declared a quarterly cash dividend of $26.35 per share (equivalent to $0.65875 per depositary share...
Brown & Brown, Inc. announces fourth quarter 2025 results, including t...
Brown & Brown, Inc. announces fourth quarter 2025 results, including total revenues of $1.6 billion, an increase of 35.7%; Organic Revenue decrease of 2.8%; diluted net income per share of $0.59; and Diluted Net Income Per Share - Adjusted of $0.93 DAYTONA BEACH, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE:BRO) (the "Company") announced its unaudited financial results for the fourth quarter and full year of 2025. For the fourth quarter ended December 31, 2025, the Company achieved: Total revenues of $1.6 billion, increasing $423 million, or 35.7%, compared to the f...
Brown & Brown mourns the passing of Chief Legal Officer Robert Mathis
Brown & Brown mourns the passing of Chief Legal Officer Robert Mathis DAYTONA BEACH, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- It is with profound sadness that Brown & Brown, Inc. (NYSE: BRO) (“the Company”) announces the passing of Chief Legal Officer, Robert Mathis. A great friend and teammate, Robert was a dynamic leader, an exceptional attorney and keen legal mind. He brought clarity to complexity, steadiness to challenging moments and genuine care to every relationship. His impact on our organization and on all who had the privilege to work alongside him is immeasurable. “Rob set the...
Brown & Brown launches fully integrated National Healthcare Practice
Brown & Brown launches fully integrated National Healthcare Practice An integrated national practice delivering comprehensive healthcare risk, insurance and brokerage solutions DAYTONA BEACH, Fla., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE: BRO) (“the Company”) today announced the launch of a fully integrated, all-lines National Healthcare Practice — Brown & Brown Healthcare. This major step brings together more than 140 seasoned professionals into a specialized team dedicated to delivering comprehensive, innovative risk solutions for the full spectrum of healthcare o...
Brown & Brown, Inc. announces quarterly cash dividend
Brown & Brown, Inc. announces quarterly cash dividend DAYTONA BEACH, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE: BRO) announces that the board of directors has declared a regular quarterly cash dividend of $0.165 per share. The dividend is payable on February 11, 2026, to shareholders of record on February 4, 2026. About Brown & Brown, Inc. Brown & Brown, Inc. (NYSE: BRO) is a leading insurance brokerage firm delivering comprehensive and customized insurance solutions and specialization since 1939. With a global presence spanning 700+ locations and a team of more...
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corp...
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. “We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. “Laura’s tw...
Bread Financial Schedules Fourth Quarter and Full Year 2025 Earnings C...
Bread Financial Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call for Jan. 29 COLUMBUS, Ohio, Jan. 06, 2026 (GLOBE NEWSWIRE) -- (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions will host a conference call on Thursday, Jan. 29, 2026, at 8:30 a.m. ET to discuss the company’s fourth quarter and full year 2025 results. Conference Call/Webcast InformationParticipants can register in advance , and the conference call will be available at the company’s . Analysts planning to participate in the Q&...
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug ...
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLA ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to the ONS-5010/LYTENAVA™ (bevacizumab-vikg) biologics license...
Brown & Brown, Inc. announces 2025 fourth-quarter earnings release and...
Brown & Brown, Inc. announces 2025 fourth-quarter earnings release and conference call dates DAYTONA BEACH, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE: BRO) announces it will release its 2025 fourth-quarter earnings on Monday, January 26, 2026, after the close of the market. On Tuesday, January 27, 2026, J. Powell Brown, Brown & Brown’s president and chief executive officer, and R. Andrew Watts, Brown & Brown’s executive vice president and chief financial officer, will host an investor update conference call concerning Brown & Brown's fourth-quarter 2025 financial r...
Outlook Therapeutics Announces New Employment Inducement Grants
Outlook Therapeutics Announces New Employment Inducement Grants ISELIN, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that effective December 19, 2025, the Outlook Therapeutics, Inc. Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 150,000 shares of Outlook Therapeutics common stock with a per share exercise price of $2.01 per share to two new employees. The above-described awards were gran...
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for fiscal year 2025. Financial Highlights for the Fiscal Year Ended September 30, 2025 For the fiscal year ended September 30, 2025, Outlook Therapeutics reported net loss attributable to common stockholders of $62.4 million, or $1.79 per basic and diluted share, and $1.4 million of revenue. This com...
Brown & Brown, Inc. acquires the assets of J. Kevin Campbell Agency
Brown & Brown, Inc. acquires the assets of J. Kevin Campbell Agency DAYTONA BEACH, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- J. Scott Penny, chief acquisitions officer of Brown & Brown, Inc. (NYSE:BRO), and Kevin Campbell, principal of the J. Kevin Campbell Agency, Inc. (“Campbell Agency”), today announced that a subsidiary of Brown & Brown, Inc. has acquired the assets of the Campbell Agency. The Campbell Agency was founded in 1991 by Kevin Campbell, with a focus on delivering best-in-class workers’ compensation insurance solutions for its customers. Kian Ostovar joined the organization i...
- Geoffrey Von Der Ahe
- Ritika Das
- Robert Driscoll
Bread Financial Provides Performance Update for November 2025
Bread Financial Provides Performance Update for November 2025 COLUMBUS, Ohio, Dec. 10, 2025 (GLOBE NEWSWIRE) -- (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company’s net loss rate and delinquency rate for the periods indicated: For themonth endedNovember 30, 2025 For themonth endedNovember 30, 2024 (dollars in millions)End-of-period credit card and other loans$18,094 $18,143 Average credit card and other ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.